Four of 8 patients treated with oleclumab monotherapy showed a twofold decrease of CD73 expression on treatment, with a concomitant ≥ twofold increase in CD8+ T cell infiltration in tumor tissues, providing preliminary evidence of immunomodulation by oleclumab in patients with MSS-CRC and PDAC. Here, NT5E is linked to neoplasm.